Sign In
Buy CLVS
$0.151
+0 (+0%)
At Close: Apr 19, 2023
The Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market will grow by USD 810.23 mn during 2020-2024
Clovis Oncology Announces First Patient Enrolled in the Phase 2 Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in ...
Clovis Oncology (CLVS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
04:33pm, Thursday, 30'th Jul 2020
Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clovis Oncology to Announce Second Quarter 2020 Financial Results and Host Webcast Conference Call on August 6
12:00pm, Thursday, 23'rd Jul 2020
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2020 financial results on Thursday, August 6, 2020, after the close of the U.S. financial markets. Clovis’ senior management wil
Clovis (CLVS) Upgraded to Buy: Here's Why
04:00pm, Tuesday, 21'st Jul 2020
Clovis (CLVS) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Have Insiders Been Buying Clovis Oncology, Inc. (NASDAQ:CLVS) Shares?
01:17pm, Wednesday, 15'th Jul 2020
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
Hedge Funds Never Been Less Bullish On Clovis Oncology Inc (CLVS)
06:46pm, Tuesday, 30'th Jun 2020
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that sm
Is Clovis Oncology (CLVS) Stock a Solid Choice Right Now?
12:37pm, Tuesday, 23'rd Jun 2020
Clovis Oncology (CLVS) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.
Alkermes plc (Nasdaq: ALKS) and Clovis Oncology, Inc. (Nasdaq: CLVS) today announced positive preclinical data from a study designed to evaluate the combination potential of ALKS 4230, Alkermes' inves
Clovis Oncology to Highlight Rubraca® (rucaparib) and Lucitanib Non-Clinical Data at the AACR Virtual Annual Meeting II 2020
12:00pm, Wednesday, 17'th Jun 2020
Clovis Oncology to Highlight Rubraca® (rucaparib) and Lucitanib Non-Clinical Data at the AACR Virtual Annual Meeting II 2020
Clovis Oncology to Highlight Rubraca® (rucaparib) and Lucitanib Non-Clinical Data at the AACR Virtual Annual Meeting II 2020
12:00am, Wednesday, 17'th Jun 2020
Clovis Oncology to Highlight Rubraca® (rucaparib) and Lucitanib Non-Clinical Data at the AACR Virtual Annual Meeting II 2020
Biogen's NURTURE Data, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:BIIB)
08:55am, Tuesday, 16'th Jun 2020
Biogen reports positive data from the NURTURE study. Magenta quits inherited metabolic disorder study. Clovis completes enrolment in RUBRACA study.
Clovis Completes Enrollment in Late-Stage Ovarian Cancer Study
02:49pm, Thursday, 11'th Jun 2020
Clovis (CLVS) is developing Rubraca as monotherapy as well as in combination with Bristol-Myers' Opdivo as first-line maintenance treatment for ovarian cancer in the phase III ATHENA study.
The Daily Biotech Pulse: Sorrento Submits EUA Application For Rapid Coronavirus Test, Decision Day For Viela, Lantern Pharma IPO
12:12pm, Thursday, 11'th Jun 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 10) * AbbVie Inc (NYSE: ABBV) - announced an oncology pa
